Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Moderna Inc shares valued at $8,736 were purchased by Hussain Abbas on Jun 11 ’25. At $28.00 per share, Hussain Abbas acquired 312 shares.
Also, Bancel Stephane purchased 160,314 shares, netting a total of over 5,004,318 in proceeds. Following the buying of shares at $31.22 each, the insider now holds 9,210,686 shares.
Before that, SAGAN PAUL had added 31,620 shares to its account. In a trade valued at $1,004,251, the Director bought Moderna Inc shares for $31.76 each. Upon closing the transaction, the insider’s holdings increased to 31,620 shares, worth approximately $8.66 million.
As published in their initiating research note from Citigroup on March 13, 2025, Moderna Inc [MRNA] has been a Neutral and the price target has been revised to $40. Analysts at Barclays downgraded the stock from ‘”an Overweight”‘ to ‘”an Equal weight”‘ outlook in a report released in mid February. As of January 29, 2025, Goldman has decreased its “Buy” rating to a “Neutral” for MRNA. Earlier on December 18, 2024, Argus downgraded its rating. Their new recommendation was “a Hold” for MRNA stock which previously was a “a Buy”.
Analyzing MRNA Stock Performance
During the last five days, there has been a surge of approximately 1.76%. Over the course of the year, Moderna Inc shares have dropped approximately -33.26%. Shares of the company reached a 52-week high of $48.92 on 01/07/25 and a 52-week low of $23.15 on 04/07/25.
Support And Resistance Levels for Moderna Inc (MRNA)
According to the 24-hour chart, there is a support level at 27.34, which, if violated, would cause prices to drop to 26.93. In the upper region, resistance lies at 28.44. The next price resistance is at 29.13. RSI (Relative Strength Index) is 54.18 on the 14-day chart, showing neutral technical sentiment.
